Author: Capuani, Silvia ; Catalano, Carlo ; Manganaro, Lucia ; Camilli, Arianna ; Giancotti, Antonella ; Petrillo, Roberta ; Ricci, Paolo ; Antonelli, Amanda ; Ercolani, Giada ; Satta, Serena ; Ciulla, Sandra ; Grimm, Robert

PURPOSETo investigate the use of IntraVoxel Incoherent Motion (IVIM) MRI in the study of microstructural tissue changes occurring in fetal lung and kidney during gestation.METHODS34 normal pregnancies were enrolled. Patients were divided into two groups based on gestational age (GA): group A (21-29 weeks) and group B (30-39 weeks). MR examinations were performed at 1.5T, with a standard fetal MR protocol including a Diffusion-Weighted Echo-Planar Imaging sequence with 10 different b-values (0, 10, 30, 50, 75, 100, 200, 400, 700, 1000s/mm²). For each fetus, two bilateral ROIs were manually placed in lung and renal parenchyma. Mean values of perfusion fraction f, pseudo-diffusion coefficient D* and diffusion coefficient D were obtained. The correlation between IVIM parameters and GA was investigated.RESULTSIn renal ROIs a positive correlation between f_kidney and GA (p < 0.005) was found; similarly f_lung showed a statistically significant correlation with GA (p < 0.001). F mean values were significantly higher in group B compared to group A in both renal (p = 0.0002) and lung (p = 0.018) ROIs. No correlation was found in D and D* as a function of GA.CONCLUSIONSThe IVIM perfusion fraction f may be considered as a potential marker of pulmonary and renal maturation in relation to hemodynamic changes described in intrauterine life. Our results highlight that IVIM model is useful as an additional prenatal diagnostic tool to study lung and renal development.

01 Nov 2017·Acta Crystallographica Section A Foundations and AdvancesQ3 · MATERIALS SCIENCE

About difference electron densities and their properties

Q3 · MATERIALS SCIENCE

Article

Author: Cascarano, Giovanni Luca ; Polidori, Giampiero ; Carrozzini, Benedetta ; Burla, Maria Cristina ; Giacovazzo, Carmelo

Difference electron densities do not play a central role in modern phase refinement approaches, essentially because of the explosive success of the EDM (electron-density modification) techniques, mainly based on observed electron-density syntheses. Difference densities however have been recently rediscovered in connection with theVLD(Vive la Difference) approach, because they are a strong support for strengthening EDM approaches and forab initiocrystal structure solution. In this paper the properties of the most documented difference electron densities, here denoted asF−Fp,mF−FpandmF−DFpsyntheses, are studied. In addition, a fourth new difference synthesis, here denoted as {\overline F_q} synthesis, is proposed. It comes from the study of the same joint probability distribution function from which theVLDapproach arose. The properties of the {\overline F_q} syntheses are studied and compared with those of the other three syntheses. The results suggest that the {\overline F_q} difference may be a useful tool for making modern phase refinement procedures more efficient.

01 May 2007·HNOQ4 · MEDICINE

Die Behandlung laryngealer Bewegungsstörungen mit Botulinumtoxinen

Q4 · MEDICINE

Review

Author: Schwemmle, C ; Ptok, M

Laryngeal dystonia (spasmodic dysphonia) is a movement disorder characterised by involuntary contractions of the laryngeal muscles involved in vocalisation. The introduction of botulinum toxin (BTX) in the treatment of laryngeal dystonia had a major clinical impact due to the striking improvement of symptoms. Most patients with severe types of spasmodic dysphonia are treated with injections of botulinum toxin type A. For patients with a resistance against type A toxin there is a new hypercleaned type A toxin or type B available. Research on type F toxin is also underway. In this article, the history of botulinum toxin, its therapeutic activity and possibilities for its use are described.

100 Deals associated with Recombinant human histone H1.3(SymBio Pharmaceuticals)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 2	-	Pharmsynthez PJSC	-
Acute Myeloid Leukemia	Phase 2	-	SymBio Pharmaceuticals Ltd.	-
Acute Myeloid Leukemia	Phase 2	-	Xenetic Biosciences, Inc.	-
Acute Myeloid Leukemia	Phase 2	-	Dana-Farber Cancer Institute, Inc.	-
Non-Hodgkin Lymphoma	Phase 2	-	Xenetic Biosciences, Inc.	-
Non-Hodgkin Lymphoma	Phase 2	-	SymBio Pharmaceuticals Ltd.	-
Non-Hodgkin Lymphoma	Phase 2	-	Dana-Farber Cancer Institute, Inc.	-
Non-Hodgkin Lymphoma	Phase 2	-	Pharmsynthez PJSC	-
Acute Myeloid Leukemia	Preclinical	Russia	-	-
Acute Myeloid Leukemia	Preclinical	Germany	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2009	Phase 1	HR-positive/HER2-low Solid Tumors	74	FOLFIRI + F	(eualskosoa) = zeemjbovrr nrwzietdlb (mfcvzxbgkt )	-	20 May 2009
ASCO2006	Not Applicable	Recurrent Prostate Carcinoma	26	CAB+F	dogxbxhxcl(gokijtbtap) = szobmxjuiy gmlrtwqnup (phzuczwjjz ) View more	-	20 Jun 2006
ASCO2006	Not Applicable	Recurrent Prostate Carcinoma	26	ZA	dogxbxhxcl(gokijtbtap) = hxycevhoar gmlrtwqnup (phzuczwjjz ) View more	-	20 Jun 2006

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Recombinant human histone H1.3(SymBio Pharmaceuticals)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation